Study of Colchicine Resistance in Familial Mediterranean Fever

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jun 10, 2022

Keywords

ClinConnect Summary

Patients meeting the criteria for colchicine resistance will be included in a follow-up visit.

* Adherence to colchicine therapy will be assessed by the Girerd questionnaire completed by the patient at the inclusion visit.
* A blood test is performed including a haemogram, CRP and SAA, creatinine and proteinuria.
* a standard stool analysis on site to look for C. difficile toxin.

For research purposes, samples of:

* Stool.
* A strand of hair with the diameter of a pencil and a minimum length of 2 cm, in the region of the posterior vertex, where the growth and integration are relatively c...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Inclusion Criteria Age ≥ 12 years with no upper age limit -Patients with familial Mediterranean fever (FMF) meeting international criteria for the disease (Livneh criteria) and carrying 2 pathogenic mutations in the MEFV gene.
• Patients considered colchicine-resistant according to EULAR criteria reviewed by an expert consensus:
• • Persistence of signs of activity (at least one attack per month for at least 3 months) despite taking the maximum tolerated dosage of colchicine.
• • Persistence of a biological inflammatory syndrome after exclusion of other causes and despite taking a maximum tolerated dosage of colchicine.
• • Signature of an informed consent by the patient (or his parents if under 18 years of age)
• • Patients affiliated to a social security system
• Exclusion Criteria:
• • - Patients participating in another interventional trial